
4-Amino-6-methylpyrimidine | CAS:3435-28-7
4-Amino-6-methylpyrimidine
- 名称:4-氨基-6-甲基嘧啶 | 4-Amino-6-methylpyrimidine
- CAS号:3435-28-7
- 别名:
- 分子式:C5H7N3
- 分子量:109.13
- EINESC号:
产品描述
物理化学性质
没有数据 | 没有数据 |
---|
安全数据
没有数据 | 没有数据 |
---|
产品合成路线
名称 | CAS号 |
---|
更多
文章
同行评议文献
Double-blind treatment of apathy in patients with poststroke depression using nefiracetam.Robert G Robinson et al.The Journal of neuropsychiatry and clinical neurosciences, 21(2), 144-151 (2009-07-23)
Nefiracetam. DM 9384, DZL 221, Translon. Drugs in R&D, 3(3), 212-216 (2002-07-09)
Early pathophysiological features in canine renal papillary necrosis induced by nefiracetam.Yoshimi Tsuchiya et al.Toxicologic pathology, 33(5), 561-569 (2005-08-18)
CaM kinase II and protein kinase C activations mediate enhancement of long-term potentiation by nefiracetam in the rat hippocampal CA1 region.Shigeki Moriguchi et al.Journal of neurochemistry, 106(3), 1092-1103 (2008-05-01)
Effects of nefiracetam on the levels of brain-derived neurotrophic factor and synapsin I mRNA and protein in the hippocampus of microsphere-embolized rats.Tsuyoshi Ando et al.European journal of pharmacology, 507(1-3), 49-56 (2005-01-22)
Negative regulation of opioid receptor-G protein-Ca2+ channel pathway by the nootropic nefiracetam.Mitsunobu Yoshii et al.Annals of the New York Academy of Sciences, 1025, 389-397 (2004-11-16)
Dopaminergic D1 receptor signalling is necessary, but not sufficient for cued fear memory destabilisation.Charlotte R Flavell et al.Psychopharmacology, 236(12), 3667-3676 (2019-08-09)
Pharmacological study on Alzheimer's drugs targeting calcium/calmodulin-dependent protein kinase II.Shigeki Moriguchi Journal of pharmacological sciences, 117(1), 6-11 (2011-08-09)
Apathy following stroke.Ricardo E Jorge et al.Canadian journal of psychiatry. Revue canadienne de psychiatrie, 55(6), 350-354 (2010-06-15)
Improvement of depressive behaviors by nefiracetam is associated with activation of CaM kinases in olfactory bulbectomized mice.Feng Han et al.Brain research, 1265, 205-214 (2009-02-24)
Nefiracetam activation of CaM kinase II and protein kinase C mediated by NMDA and metabotropic glutamate receptors in olfactory bulbectomized mice.Shigeki Moriguchi et al.Journal of neurochemistry, 110(1), 170-181 (2009-05-22)
Double-blind randomized treatment of poststroke depression using nefiracetam.Robert G Robinson et al.The Journal of neuropsychiatry and clinical neurosciences, 20(2), 178-184 (2008-05-03)
Discriminative-stimulus effects of methamphetamine and morphine in rats are attenuated by cAMP-related compounds.Yijin Yan et al.Behavioural brain research, 173(1), 39-46 (2006-07-22)
Nootropic nefiracetam inhibits proconvulsant action of peripheral-type benzodiazepines in epileptic mutant EL mice.Yurie Nakamoto et al.Annals of the New York Academy of Sciences, 1025, 135-139 (2004-11-16)
[Evaluation methods for the discriminative stimulus and possible mechanisms of discriminative stimulus effects of methamphetamine in the rat].Hiroyuki Mizoguchi et al.Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 126(1), 17-23 (2005-09-06)
Effects of Nefiracetam, a novel pyrrolidone-type nootropic agent, on the amygdala-kindled seizures in rats.Yutaka Kitano et al.Epilepsia, 46(10), 1561-1568 (2005-09-30)
Nefiracetam, a novel cognition-enhancing agent. An introductory overview.M Tanaka et al.Arzneimittel-Forschung, 44(2A), 193-194 (1994-02-01)
Testicular toxicity induced in dogs by nefiracetam, a neutrotransmission enhancer.Kazuhiro Shimomura et al.Reproductive toxicology (Elmsford, N.Y.), 18(3), 423-430 (2004-04-15)
Anticonvulsant and neuroprotective effects of the novel nootropic agent nefiracetam on kainic acid-induced seizures in rats.Yutaka Kitano et al.Brain research, 1057(1-2), 168-176 (2005-08-27)
Nefiracetam and galantamine modulation of excitatory and inhibitory synaptic transmission via stimulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.S Moriguchi et al.Neuroscience, 160(2), 484-491 (2009-03-11)
Improving Nefiracetam Dissolution and Solubility Behavior Using a Cocrystallization Approach.Xavier Buol et al.Pharmaceutics, 12(7) (2020-07-15)
Anticonvulsant properties of the novel nootropic agent nefiracetam in seizure models of mice and rats.Yutaka Kitano et al.Epilepsia, 46(6), 811-818 (2005-06-11)
Chronic exposure of rats to cognition enhancing drugs produces a neuroplastic response identical to that obtained by complex environment rearing.Keith J Murphy et al.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 31(1), 90-100 (2005-07-01)
Mechanisms of action of cognitive enhancers on neuroreceptors.Toshio Narahashi et al.Biological & pharmaceutical bulletin, 27(11), 1701-1706 (2004-11-02)
Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor.Shigeki Moriguchi et al.Molecular pharmacology, 71(2), 580-587 (2006-11-11)
Nefiracetam attenuates post-ischemic nonconvulsive seizures in rats and protects neuronal cell death induced by veratridine and glutamate.Xi-Chun May Lu et al.Life sciences, 92(22), 1055-1063 (2013-04-23)
[Facilitatory actions of the cognitive enhancer nefiracetam on neuronal Ca2+ channels and nicotinic ACh receptors: their intracellular signal transduction pathways].M Yoshii et al.Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 112 Suppl 1, 41P-43P (1999-04-06)
Investigation on urinary proteins and renal mRNA expression in canine renal papillary necrosis induced by nefiracetam.Yoshimi Tsuchiya et al.Archives of toxicology, 79(9), 500-507 (2005-07-12)
Nefiracetam attenuates methamphetamine-induced discriminative stimulus effects in rats.Yijin Yan et al.Annals of the New York Academy of Sciences, 1025, 274-278 (2004-11-16)
Dysregulation of BRD4 Function Underlies the Functional Abnormalities of MeCP2 Mutant Neurons.Yangfei Xiang et al.Molecular cell, 79(1), 84-98 (2020-06-12)
备注
Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at buyer's risk.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271 +A13(1).
名称 | CAS号 |
---|

相关产品
相关资讯
问
热门标签
询 单
请 填 写 相 关 信 息
- 请填写产品名称!
- CAS号
- 请正确填写公司名称!
- 请正确填写联系人!
- 请正确填写联系电话!
- 请正确填写联系邮箱!
- 请描述您的问题!